Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia. (CLL0911)
|ClinicalTrials.gov Identifier: NCT01762202|
Recruitment Status : Active, not recruiting
First Posted : January 7, 2013
Last Update Posted : March 22, 2018
|Condition or disease||Intervention/treatment||Phase|
|B-cell Lymphoid Leukemia Young Patients||Drug: Cyclophosphamide Drug: Fludarabine Drug: Ofatumumab||Phase 2|
- rituximab, fludarabine and cyclophosphamide (FCR) front-line treatment was associated with a high OR rate, superior PFS and OS as compared to fludarabine and cyclophosphamide regimen;
- a direct relationship between the dose of rituximab and the response rate has been reported;
- ofatumumab, as single agent, proved activity in CLL patients with refractory disease;
- ofatumumab, fludarabine and cylophosphamide (O-FC) front-line treatment has been associated with a high complete response (CR) rate;
- the expected grade 3-4 granulocytopenia could led to reduce the dose intensity of study drugs (FC) and increase the infection rate; a schedule combining FC with an increased dose of ofatumumab associated to primary phrophylaxis of granulocytopenia could be associated with an improvement in the CR rate. The purpose of this study is to determine whether we could improve the CR rate of the golden standard treatment for fit patients with CLL , the FCR regimen, with a chemoimmunotherapy including FC combined with an increased dose of the monoclonal antibody ofatumumab, given every other week (FCO2) associated with a primary prophylaxis of granulocytopenia.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 2 Multicenter, Study to Assess the Efficacy and the Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab (FCO2) Chemoimmunotherapy in Young (≤65 Yrs) Patients With Chronic Lymphocytic Leukemia (CLL).|
|Study Start Date :||November 2013|
|Actual Primary Completion Date :||November 2015|
|Estimated Study Completion Date :||May 2018|
|Experimental: Study therapy||
- Number of complete responses. [ Time Frame: After 8 months from study entry. ]The complete response (CR) rate after FCO2 front-line treatment.
- Number of overall responses. [ Time Frame: After 8 months from study entry. ]Overall Response (OR) rate after FCO2 front-line treatment.
- Number of patients in progression-free survival. [ Time Frame: After 32 months from study entry. ]Progression-free survival (PFS) calculated from the date of first treatment dose - induction phase - until the date of the first documentation of progressive disease or until death (whatever the cause), whichever occurs first. Patients still alive and known to be progression free will be censored at the moment of last follow-up.
- Number of patients needing a new CLL Treatment. [ Time Frame: After 32 months from study entry. ]Time to a new CLL treatment (TTT) will be calculated from the date of last treatment dose until date of a new treatment received for CLL, where death occurred before the new treatment will be considered as competing risk. Patients still alive without receiving a new treatment will be censored at the time of the last follow-up.
- Number of patients in overall survival [ Time Frame: After 32 months from study entry. ]Overall survival (OS): defined as the time interval between the date of first treatment dose - induction phase- and the date of death for any cause; patients still alive will be censored at the moment of last follow-up.
- Number of toxic events. [ Time Frame: After 32 months from study entry. ]Toxicity of treatment according the last NCI criteria.
- Outcome of patients according to clinical and biologica variables. [ Time Frame: After 32 months from study entry. ]Outcome of patients (response, PFS OS) according to clinical and biologic variables (age; size of nodes, 2-microglobulin, lymphocyte count, stage, IgVH, p53, FISH, ZAP-70, CD38, FLCs).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01762202
|S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo|
|Dipartimento Area Medica - Presidio Ospedaliero "C. e G.Mazzoni"|
|Ascoli Piceno, Italy|
|S.O.C. di Medicina Interna B - Ospedale - Cardinal Massaia di Asti|
|ASL12 - Biella Ospedale degli Infermi - Dip. di Medicina e Geriatria - Struttura Complessa di Medicina Interna|
|Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia|
|Sezione di Ematologia e Fisiopatologia delle Emostasi - Azienda Ospedaliera - Arcispedale S. Anna|
|RCCS_AOU San Martino-IST-Ematologia 1-Monoblocco 11°piano- lato ponente|
|ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE|
|Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina|
|Ospedale Niguarda " Ca Granda"|
|S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro|
|Divisione di Ematologia con trapianto di midollo - A.U. Policlinico "Paolo Giaccone"|
|Cattedra di Ematologia CTMO Università degli Studi di Parma|
|Dipartimento Emato-Oncologia A.O."Bianchi-Melacrino-Morelli"|
|Reggio Calabria, Italy|
|Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova|
|Reggio Emilia, Italy|
|Padiglione Cesalpino - I piano - Divisione di Ematologia - Ospedale S. Camillo|
|Policlinico Umberto I, Hematology Department - Sapienza|
|U.O.C. Ematologia - Ospedale S.Eugenio|
|U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico " Le Scotte"|
|SS.C. di Oncoematologia - Dipartimento di Medicina Clinica e Sperimentale - Azienda Ospedaliera - S. Maria Di Terni|
|Div. di Ematologia Ospedale "S.Giovanni Battista"|
|Clinica Ematologica - Policlinico Universitario|
|Study Chair:||Roberto Foà, Pr.||Policlinico Umberto I, Hematology Department.|
|Study Director:||Francesca R. Mauro||Policlinico Umberto I, Hematology Department.|